FiercePharmaAsia—Takeda’s hard-won Shire deal and Nektar I-O pact; Daiichi’s DMD flop
admin 27th April 2018 Uncategorised 0It took five tries, but Takeda finally persuaded Shire to consider a buyout bid; Nektar and Takeda paired up their candidates in a non-Hodgkin lymphoma trial; Daiichi Sankyo pushed its DMD prospect ahead despite mixed early-phase data; Indian drugmakers were slapped by manufacturing regulators; plus more pharma industry news from Asia.
More: FiercePharmaAsia—Takeda’s hard-won Shire deal and Nektar I-O pact; Daiichi’s DMD flop
Source: fierce